Protean BioDiagnostics Partners with Arima Genomics

Protean BioDiagnostics partners with Arima to make gene fusion testing widely available to patients.

Anthony MaglioccoFebruary 1, 2023

Protean Presents Project DelPHI at AMP 22

Protean presents two case studies this year at AMP 22, on the use of DelPHI, Protean MAPS, and Navify Digital Tools for the timely diagnosis and/or treatment of cancer.

Anthony MaglioccoNovember 1, 2022

Protean Presents on the Importance of Precision Medicine in Uncovering a Patient's True Diagnosis at AMP 22

Protean presents a case study that highlights the ability to catch a liver carcinoma misdiagnosis using pathology review, comprehensive in-house molecular testing, and virtual molecular tumor boards.

Anthony MaglioccoOctober 20, 2022

Protean BioDiagnostics, Inc. Partners with Qualisure Diagnostics, Inc.

Protean BioDiagnostics Enhances Thyroid Cancer Care for Patients with the addition of the Latest Leading Test to its Protean MAPS™ Diagnostic Menu.

Anthony MaglioccoSeptember 6, 2022

Protean Will Provide Results From a Study of Endometrial Cancer in African Americans and Caucasian Americans at ASCO 2022 in Chicago

African American patients have a worse outcome, regardless of the molecular subtype of cancer. In White patients molecular subtypes were associated with better outcomes.

Anthony MaglioccoMay 31, 2022

The Impact of Molecular Features on Outcome in Black Women With Type 1 Endometrial Cancer

Among women with endometrial cancer (EC), African American or Black (AAoB) population share a disproportionate burden of cancer deaths. Here, we aim to focus on molecular differences between racial groups, specifically in Type 1 EC (T1EC).

Anthony MaglioccoMay 17, 2022